OR WAIT null SECS
November 15, 2023
Novartis and Legend Biotech seek to advance certain CAR-T cell therapy candidates targeting Delta-like ligand protein 3.
November 14, 2023
A discussion with Thomas Langenickel, MD, chief medical officer at Ethris, shines a light on how advances made with mRNA technology are also advancing the industry’s ability to focus on treatment of rare diseases, such as rare lung diseases.
November 08, 2023
Matthew Lauber, senior director—Cell and Gene Therapy, Consumables & Lab Automation, at Waters Corporation highlights how current technologies are enabling oligonucleotide development.
Matthew Lauber, senior director—Cell and Gene Therapy, Consumables & Lab Automation, at Waters Corporation, considers that status of oligonucleotides on the market.
Innovative strategies and good partnerships are means by which developers can overcome the unique challenges in biologics formulation.
November 07, 2023
Matthew Lauber, senior director—Cell and Gene Therapy, Consumables & Lab Automation, at Waters Corporation discusses the analytical and downstream purification challenges of oligonucleotides.
November 06, 2023
The Alliance for mRNA Medicines (AMM) was officially launched at the 11th International mRNA Health Conference in Berlin, Germany.
October 18, 2023
Spark Therapeutics and SpliceBio have formed a collaboration to develop a gene therapy that can treat an inherited retinal disease.
The California Institute for Regenerative Medicine has partnered with Forge Biologics, which will manufacture AAVs to help accelerate gene therapy programs in California.
October 13, 2023
Under an expanded agreement, Cellares will provide proof-of-concept manufacturing for a second CAR-T cell therapy from Bristol Myers Squibb.